IGC Pharma, Inc.

IGC

AMEX

Healthcare

Biotechnology

Potomac, MD, US67 employeesigcpharma.com

$0.27

-0.01(-1.84%)

Mkt Cap $26M

$0.25

$0.47

52-Week Range

At a Glance

AI-generated

Revenue breakdown: Plant And Cannabinoid (48.5%), Tolling White Labeling Service (39.1%), Wellness And Lifestyle (6.3%).

8-K

IGC Pharma, Inc. entered into a Securities Purchase Agreement on March 5, 2026, issuing a $353,050 principal promissory note (with $46,050 OID) to Vanquish Funding Group Inc. for $307,000, maturing February 28, 2027, convertible upon default at 75% of the lowest trading price over prior 10 trading days. The Company also received approximately $219,000 under a loan agreement with One Deck Capital, Inc. for general working capital purposes.

$26M

Market Cap

—

Revenue

—

Net Income

Employees67

Fundamentals

How The Business Makes Money

Revenue by Segment

Plant And Cannabinoid48.5%($3M)

Tolling White Labeling Service39.1%($2M)

Wellness And Lifestyle6.3%($341.0K)

Infrastructure Segment3%($164.0K)

Other Revenue3%($164.0K)

Revenue by Geography

US93.6%($2M)

IN6.3%($164.0K)

CO0.2%($4.0K)

Activity

What Changed Recently

Material Agreement

Mar 11, 2026

Entry into a Material Definitive Agreement. On March 5, 2026, IGC Pharma, Inc. (“IGC” or the “Company”) entered into a Securities Purchase Agreement (the “Purch

Material Agreement

Jan 5, 2026

Entry into a Material Definitive Agreement. On January 5, 2026, IGC Pharma, Inc. (“IGC” or the “Company”) entered into a Subscription Agreement (the “2025 Subsc

Other Event

Mar 29, 2026

, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor

Peer Companies

Company	Price	Change	Market Cap	P/E
ANTXAN2 Therapeutics, Inc.	$3.29	-4.78%	$90M	-3.3
QTTBQ32 Bio Inc.	$6.45	+5.56%	$79M	2.8
NTRBNutriband Inc.	$3.75	+4.17%	$46M	-3.6
SABSSAB Biotherapeutics, Inc.	$3.88	+0.13%	$37M	5.7
NXTCNextCure, Inc.	$10.74	+1.99%	$29M	-0.7
PLURPluri Inc.	$3.32	-0.90%	$27M	-1.1
BOLDBoundless Bio, Inc.	$1.09	-3.54%	$24M	-0.4
INTSIntensity Therapeutics, I...	$5.66	-0.52%	$11M	-0.9

Analyst View

Company Profile

CIK0001326205

ISINUS45408X3089

CUSIP45408X308

Phone301 983 0998

Address10224 Falls Road, Potomac, MD, 20854, US

SEC EDGAR